Adial Pharmaceuticals (ADIL) announced patent number 12,226,401 was issued on February 18, 2025 by the United States Patent and Trademark Office, or USPTO, expanding coverage of Adial’s genetic-based approach to treating and diagnosing alcohol use disorder and other drug dependencies. The new patent covers claims that focus on a method for identifying genetic markers in patients with alcohol or opioid-related disorders. With the identification of specific genotypes, including the AC genotype of rs17614942 in the HTR3B gene and the AG genotype of rs1150226 in the HTR3A gene, providers will be able to provide tailored treatment plans using AD04, the Company’s investigational new drug product. This patent also expands the identification of possible treatment candidates for AD04 administration depending on the patient’s unique genetic profile. By aligning therapeutic approaches with genetic data, the AD04 precision medicine approach is designed to deliver optimal outcomes while reducing risks associated with one-size-fits-all approaches.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADIL:
- Adial Pharmaceuticals awarded new U.S. patent on genotype-specific treatment
- Adial Pharmaceuticals announce clinical study results from AD04-103 study
- Adial Pharmaceuticals Focuses on Strategic Growth Initiatives
- Adial Pharmaceuticals Highlights AD04 for Alcohol Use Disorder
- Adial Pharmaceuticals files to sell 5.0M shares of common stock for holders
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue